209 related articles for article (PubMed ID: 6767876)
1. Basic issues in population screening for cancer.
Cole P; Morrison AS
J Natl Cancer Inst; 1980 May; 64(5):1263-72. PubMed ID: 6767876
[TBL] [Abstract][Full Text] [Related]
2. Principles of cancer screening for clinicians.
Taplin SH; Mandelson MT
Prim Care; 1992 Sep; 19(3):513-33. PubMed ID: 1410061
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of cancer screening in end-stage renal disease.
Chertow GM; Paltiel AD; Owen WF; Lazarus JM
Arch Intern Med; 1996 Jun; 156(12):1345-50. PubMed ID: 8651845
[TBL] [Abstract][Full Text] [Related]
4. The cost of cancer.
Cromwell J; Gertman P
Laryngoscope; 1979 Mar; 89(3):393-409. PubMed ID: 107379
[TBL] [Abstract][Full Text] [Related]
5. Screening for cancer: evaluating the evidence.
Gates TJ
Am Fam Physician; 2001 Feb; 63(3):513-22. PubMed ID: 11272300
[TBL] [Abstract][Full Text] [Related]
6. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.
Hristova L; Hakama M
Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316
[TBL] [Abstract][Full Text] [Related]
7. Cancer screening: the importance of outcome measures.
Alibhai SM
Crit Rev Oncol Hematol; 2006 Mar; 57(3):215-24. PubMed ID: 16371251
[TBL] [Abstract][Full Text] [Related]
8. Taishotoyama Symposium Barriers to colorectal cancer screening: economics, capacity and adherence.
Inadomi JM
J Gastroenterol Hepatol; 2008 Dec; 23 Suppl 2():S198-204. PubMed ID: 19120898
[TBL] [Abstract][Full Text] [Related]
9. Health and economic benefits of well-designed evaluations: some lessons from evaluating neuroblastoma screening.
Soderstrom L; Woods WG; Bernstein M; Robison LL; Tuchman M; Lemieux B
J Natl Cancer Inst; 2005 Aug; 97(15):1118-24. PubMed ID: 16077069
[TBL] [Abstract][Full Text] [Related]
10. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
11. A perspective from countries using organized screening programs.
Miles A; Cockburn J; Smith RA; Wardle J
Cancer; 2004 Sep; 101(5 Suppl):1201-13. PubMed ID: 15316915
[TBL] [Abstract][Full Text] [Related]
12. Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it?
Havrilesky LJ; Sanders GD; Kulasingam S; Myers ER
Gynecol Oncol; 2008 Nov; 111(2):179-87. PubMed ID: 18722004
[TBL] [Abstract][Full Text] [Related]
13. Computational methods in medical decision making: to screen or not to screen?
Kafadar K; Prorok PC
Stat Med; 2005 Feb; 24(4):569-81. PubMed ID: 15678410
[TBL] [Abstract][Full Text] [Related]
14. [Mass screening program for cancer].
Fujimoto I
Gan To Kagaku Ryoho; 1984 Mar; 11(3 Pt 2):727-32. PubMed ID: 6712270
[TBL] [Abstract][Full Text] [Related]
15. Developing and testing a cost-assessment tool for cancer screening programs.
Subramanian S; Ekwueme DU; Gardner JG; Trogdon J
Am J Prev Med; 2009 Sep; 37(3):242-7. PubMed ID: 19666160
[TBL] [Abstract][Full Text] [Related]
16. Examining the cost-effectiveness of cancer screening promotion.
Andersen MR; Urban N; Ramsey S; Briss PA
Cancer; 2004 Sep; 101(5 Suppl):1229-38. PubMed ID: 15316909
[TBL] [Abstract][Full Text] [Related]
17. Improving screening practices for Barrett's esophagus.
Shaheen NJ; Palmer LB
Surg Oncol Clin N Am; 2009 Jul; 18(3):423-37. PubMed ID: 19500734
[TBL] [Abstract][Full Text] [Related]
18. Use of modeling to evaluate the cost-effectiveness of cancer screening programs.
Knudsen AB; McMahon PM; Gazelle GS
J Clin Oncol; 2007 Jan; 25(2):203-8. PubMed ID: 17210941
[TBL] [Abstract][Full Text] [Related]
19. Statistical issues in the evaluation of screening and early detection modalities.
Etzioni R
Urol Oncol; 2008; 26(3):308-15. PubMed ID: 18452826
[TBL] [Abstract][Full Text] [Related]
20. Noncompliance in cancer screening trials.
Gareen IF
Clin Trials; 2007; 4(4):341-9. PubMed ID: 17848495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
